Y-mAbs Therapeutics, Inc. (YMAB)

Market Cap	275.90M
Revenue (ttm)	84.55M
Net Income (ttm)	-23.86M
Shares Out	44.79M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	319,175
Open	6.25
Previous Close	6.18
Day's Range	6.05 - 6.31
52-Week Range	6.01 - 20.90
Beta	0.69
Analysts	Strong Buy
Price Target	21.10 (+242.53%)
Earnings Date	Feb 27, 2025

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line r...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 21, 2018
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: YMAB
• Website: https://www.ymabs.com

Financial Performance

In 2023, Y-mAbs Therapeutics's revenue was $84.82 million, an increase of 29.96% compared to the previous year's $65.27 million. Losses were -$21.43 million, -77.58% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for YMAB stock is "Strong Buy." The 12-month stock price forecast is $21.1, which is an increase of 242.53% from the latest price.

Price Target

$21.1

(242.53% upside)

Analyst Consensus: Strong Buy